Human        

GM-CSF (Ala18-Glu144), Accession # P04141  

Tag    

HEK 293        

<0.1 EU/μg of the protein by the LAL method.         

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is 0.05-0.15 ng/mL.          

Lyophilized from a 0.22μm filtered solution in 7.8mM Na₂HP04, 1.5mM KH₂PO4, 2.7mM KCl, 500mM NaCl, pH 7.4 

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder at 100 μg/mL in sterile deionized water   

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.         

12 months from date of receipt, at lower than -70 °C as supplied.

1 week, 2 to 8 °C under sterile conditions after reconstitution.

1 month, -20 to -70 °C under sterile conditions after reconstitution.

Background    

Granulocyte-macrophage colony-stimulating factor (GM-CSF) was initially classified as a hematopoietic growth factor. It is produced by a number of different cell types, including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts in response to cytokine of immune and inflammatory stimuli. GM-CSF is a vital immune system messenger that drives the production and activation of key white blood cells. Its synthetic form is a valuable medical tool primarily used to help patients recover their immune function after chemotherapy or a bone marrow transplant. Its use is a balance between achieving a beneficial immune boost and managing its potentially significant inflammatory side effects.